Stay updated with breaking news from Sysmex Inostics Gmb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path...
The Cancer Biopsy market revenues were estimated at US$ 22.2 Bn in 2022 and is anticipated to grow at a CAGR of 18% from 2023-2033, according to a recently published Future Market Insights report. By the end of 2033, the market is expected to reach US$ 131.4 Bn.The increasing elderly populace, along with the rise in...
/PRNewswire/ -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid...
Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients News provided by Share this article Share this article BALTIMORE, April 10, 2021 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster "Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients" at the 112 th Annual Meeting of the American Association for Cancer Research on April 10, 2021...
Product News: Sysmex has launched Plasma-SeqSensei liquid biopsy RUO kits in EMEA 01 Apr 2021 Sysmex Europe GmbH, together with Sysmex Inostics GmbH, has announced that they will launch the Plasma-SeqSensei™ liquid biopsy research use only (RUO) kits for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma and thyroid cancer. Liquid biopsy detects material in body fluids to assess the extent of disease, most often used for the detection of cancerous material in plasma. Though several molecular techniques are used, next generation sequencing is considered to be the most im...